BREZTRI AEROSPHERE
ICSLAMALABA MDI
Budesonide / Glycopyrrolate / Formoterol fumarate · AstraZeneca
Active Medication & Mechanism
- Budesonide ICS160 mcg per actuation (both strengths)
Corticosteroid with potent anti-inflammatory activity. Reduces airway inflammation through suppression of inflammatory cells and mediators.
- Glycopyrrolate LAMA9 mcg (COPD strength) or 18 mcg (asthma strength) per actuation
Long-acting muscarinic antagonist. Blocks M3 receptors on airway smooth muscle, inhibiting cholinergic bronchoconstriction.
- Formoterol fumarate LABA4.8 mcg per actuation
Long-acting beta2-adrenergic agonist with rapid onset. Produces sustained bronchodilation via beta2-receptor stimulation.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
160/9/4.8 mcg
2 inhalations twice daily (morning and evening) → 640/36/19.2 mcg
FDA Approved
Maintenance treatment of COPD. Triple therapy (ICS/LAMA/LABA) in a single inhaler for patients on LAMA/LABA who require additional ICS, or on ICS/LABA who require additional LAMA.
Not Approved
The 160/9/4.8 strength is the COPD strength. Only 160/18/4.8 is indicated for asthma.
160/18/4.8 mcg
2 inhalations twice daily (morning and evening) → 640/72/19.2 mcg
Not Approved
The 160/18/4.8 strength is the ASTHMA strength. Only 160/9/4.8 is indicated for COPD.
FDA Approved
Maintenance treatment of asthma, approved April 28, 2026 (first single-inhaler triple therapy for asthma in the US; KALOS/LOGOS trials). Each 2-inhalation dose delivers 320/36/9.6 mcg. Note the asthma strength (160/18/4.8) differs from the COPD strength (160/9/4.8).
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
160/9/4.8 mcg 2 inhalations twice daily (morning and evening) → 640/36/19.2 mcg
COPD FDA Approved
Maintenance treatment of COPD. Triple therapy (ICS/LAMA/LABA) in a single inhaler for patients on LAMA/LABA who require additional ICS, or on ICS/LABA who require additional LAMA.
Asthma Not Approved
The 160/9/4.8 strength is the COPD strength. Only 160/18/4.8 is indicated for asthma.
160/18/4.8 mcg 2 inhalations twice daily (morning and evening) → 640/72/19.2 mcg
COPD Not Approved
The 160/18/4.8 strength is the ASTHMA strength. Only 160/9/4.8 is indicated for COPD.
Asthma FDA Approved
Maintenance treatment of asthma, approved April 28, 2026 (first single-inhaler triple therapy for asthma in the US; KALOS/LOGOS trials). Each 2-inhalation dose delivers 320/36/9.6 mcg. Note the asthma strength (160/18/4.8) differs from the COPD strength (160/9/4.8).
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.
Related Inhalers
Other ICS + LABA + LAMA inhalers